Analysis

Wyeth's Patent Loss Has Attys Focusing On Dosage

By Dani Kass · July 21, 2026, 6:04 PM EDT

The Federal Circuit's holding that a Pfizer unit's cancer treatment patents are invalid highlights the risk of including dosages in patents without sufficient proof that those dosages work, attorneys say....

To view the full article, register now.

Documents

Case Information

Case Title

Wyeth LLC v. AstraZeneca Pharmaceuticals LP

Case Number

24-2325

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

September 17, 2024